These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 18612158

  • 1. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE.
    J Clin Oncol; 2008 Jul 10; 26(20):3426-33. PubMed ID: 18612158
    [Abstract] [Full Text] [Related]

  • 2. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
    Perez SA, Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K, Varla-Leftherioti M, Papamichail M, Thanos A, von Hofe E, Baxevanis CN.
    Clin Cancer Res; 2010 Jul 01; 16(13):3495-506. PubMed ID: 20466887
    [Abstract] [Full Text] [Related]

  • 3. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE.
    Cancer; 2008 Oct 01; 113(7):1666-75. PubMed ID: 18726994
    [Abstract] [Full Text] [Related]

  • 4. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S.
    J Clin Oncol; 2005 Oct 20; 23(30):7536-45. PubMed ID: 16157940
    [Abstract] [Full Text] [Related]

  • 5. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
    Disis ML, Grabstein KH, Sleath PR, Cheever MA.
    Clin Cancer Res; 1999 Jun 20; 5(6):1289-97. PubMed ID: 10389911
    [Abstract] [Full Text] [Related]

  • 6. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
    Knutson KL, Schiffman K, Cheever MA, Disis ML.
    Clin Cancer Res; 2002 May 20; 8(5):1014-8. PubMed ID: 12006513
    [Abstract] [Full Text] [Related]

  • 7. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
    Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA.
    J Clin Oncol; 2004 May 15; 22(10):1916-25. PubMed ID: 15143085
    [Abstract] [Full Text] [Related]

  • 8. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S.
    Clin Cancer Res; 2008 Feb 01; 14(3):797-803. PubMed ID: 18245541
    [Abstract] [Full Text] [Related]

  • 9. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.
    Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML.
    Clin Cancer Res; 2003 Nov 15; 9(15):5559-65. PubMed ID: 14654536
    [Abstract] [Full Text] [Related]

  • 10. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE.
    Clin Cancer Res; 2005 Oct 15; 11(20):7470-9. PubMed ID: 16243821
    [Abstract] [Full Text] [Related]

  • 11. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
    Patil R, Clifton GT, Holmes JP, Amin A, Carmichael MG, Gates JD, Benavides LH, Hueman MT, Ponniah S, Peoples GE.
    J Am Coll Surg; 2010 Feb 15; 210(2):140-7. PubMed ID: 20113933
    [Abstract] [Full Text] [Related]

  • 12. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
    Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE.
    Clin Cancer Res; 2006 Jan 15; 12(2):478-86. PubMed ID: 16428490
    [Abstract] [Full Text] [Related]

  • 13. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.
    Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S, Peoples GE.
    Cancer; 2010 Jan 15; 116(2):292-301. PubMed ID: 19924797
    [Abstract] [Full Text] [Related]

  • 14. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
    Benavides LC, Sears AK, Gates JD, Clifton GT, Clive KS, Carmichael MG, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE.
    Expert Rev Vaccines; 2011 Feb 15; 10(2):201-10. PubMed ID: 21332269
    [Abstract] [Full Text] [Related]

  • 15. AE37: a novel T-cell-eliciting vaccine for breast cancer.
    Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE.
    Expert Opin Biol Ther; 2011 Nov 15; 11(11):1543-50. PubMed ID: 21895539
    [Abstract] [Full Text] [Related]

  • 16. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
    Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE.
    Ann Surg Oncol; 2007 Dec 15; 14(12):3359-68. PubMed ID: 17906897
    [Abstract] [Full Text] [Related]

  • 17. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
    Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE.
    Ann Oncol; 2016 Jul 15; 27(7):1241-8. PubMed ID: 27029708
    [Abstract] [Full Text] [Related]

  • 18. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
    Melanoma Study Group of the Mayo Clinic Cancer CenterMayo Clinic Cancer Center, Rochester, Minnesota 55905, USA. markovic.svetomir@mayo.edu, Celis E.
    Cancer; 2007 Jul 01; 110(1):203-14. PubMed ID: 17541944
    [Abstract] [Full Text] [Related]

  • 19. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
    Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG.
    Clin Cancer Res; 2002 Nov 01; 8(11):3407-18. PubMed ID: 12429628
    [Abstract] [Full Text] [Related]

  • 20. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, Stojadinovic A, Mittendorf EA, Ponniah S, Peoples GE.
    Cancer; 2011 Feb 01; 117(3):463-71. PubMed ID: 20845479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.